Lipoprotein(a) Is Markedly More Atherogenic Than LDL

References 33

1. 1.

   Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925-3946.

   Not in our library10.1093/eurheartj/ehac361

2. 2.

   Kronenberg F, Mora S, Stroes ESG. Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees. Curr Opin Lipidol. 2022;33:342-352.

   Not in our library10.1097/mol.0000000000000855

3. 3.

   Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e48-e60.

   Not in our library10.1161/atv.0000000000000147

4. 4.

   Kaiser Y, van der Toorn JE, Singh SS, et al. Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification. Eur Heart J. 2022;43:3960-3967.

   Not in our library10.1093/eurheartj/ehac377

5. 5.

   Nurmohamed NS, Kraaijenhof JM, Stroes ESG. Lp(a): a New Pathway to Target? Curr Atheroscler Rep. 2022;24:831-838.

   Not in our library10.1007/s11883-022-01060-4

6. 6.

   O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139:1483-1492.

   Not in our library10.1161/circulationaha.118.037184

7. 7.

   Bittner VA, Szarek M, Aylward PE, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol. 2020;75:133-144.

   Not in our library10.1016/j.jacc.2019.10.057

8. 8.

   Nurmohamed NS, Moriarty PM, Stroes ESG. Considerations for routinely testing for high lipoprotein(a). Curr Opin Lipidol. 2022;33:213-218.

   Not in our library10.1097/mol.0000000000000838

9. 9.

   Wei T, Cho L. Recent lipoprotein(a) trials. Curr Opin Lipidol. 2022;33:301-308.

   Not in our library10.1097/mol.0000000000000856

10. 10.

    O’Donoghue ML, Rosenson RS, Gencer B, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022;387:1855-1864.

    Not in our library10.1056/nejmoa2211023

11. 11.

    Burgess S, Ference BA, Staley JR, et al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol. 2018;3:619-627.

    Not in our library10.1001/jamacardio.2018.1470

12. 12.

    Lamina C, Kronenberg F, Lp GC. Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. JAMA Cardiol. 2019;4:575-579.

    Not in our library10.1001/jamacardio.2019.1041

13. 13.

    Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Arterioscler Thromb Vasc Biol. 2020;40:255-266.

    Not in our library10.1161/atvbaha.119.312951

14. 14.

    Welsh P, Welsh C, Celis-Morales CA, et al. Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. Eur J Prev Cardiol. 2022;28:1991-2000.

    Not in our library10.1093/eurjpc/zwaa063

15. 15.

    Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41:246-255.

    Not in our library

16. 16.

    Kronenberg F. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? Atherosclerosis. 2022;349:123-135.

    Not in our library10.1016/j.atherosclerosis.2022.04.008

17. 17.
    UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age · 2015

    No notice
18. 18.

    Schunkert H, Konig IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333-338.

    Not in our library10.1038/ng.784

19. 19.

    Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42:4791-4806.

    Not in our library10.1093/eurheartj/ehab551

20. 20.

    Tsimikas S, Marcovina SM. Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;80:934-946.

    Not in our library10.1016/j.jacc.2022.06.019

21. 21.

    Harazono A, Kawasaki N, Kawanishi T, Hayakawa T. Site-specific glycosylation analysis of human apolipoprotein B100 using LC/ESI MS/MS. Glycobiology. 2005;15:447-462.

    Not in our library10.1093/glycob/cwi033

22. 22.
    A robust and efficient method for Mendelian randomization with hundreds of genetic variants · 2020

    No notice
23. 23.

    Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.

    Not in our library10.1016/s0140-6736(10)61350-5

24. 24.

    Welsh P, Welsh C, Celis-Morales CA, et al. Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. Eur J Prev Cardiol. 2022;28:1991-2000.

    Not in our library10.1093/eurjpc/zwaa063

25. 25.

    Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459-2472.

    Not in our library10.1093/eurheartj/ehx144

26. 26.

    van der Valk FM, Bekkering S, Kroon J, et al. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation. 2016;134:611-624.

    Not in our library10.1161/circulationaha.116.020838

27. 27.

    Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.

    Not in our library10.1093/eurheartj/ehq386

28. 28.

    Pan Y, Li H, Wang Y, Meng X, Wang Y. Causal Effect of Lp(a) [Lipoprotein(a)] Level on Ischemic Stroke and Alzheimer Disease: A Mendelian Randomization Study. Stroke. 2019;50:3532-3539.

    Not in our library10.1161/strokeaha.119.026872

29. 29.

    Arsenault BJ, Boekholdt SM, Dube MP, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014;7:304-310.

    Not in our library10.1161/circgenetics.113.000400

30. 30.

    Kamstrup PR, Nordestgaard BG. Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population. JACC Heart Fail. 2016;4:78-87.

    Not in our library10.1016/j.jchf.2015.08.006

31. 31.

    Larsson SC, Gill D, Mason AM, et al. Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease: Mendelian Randomization Investigation. Circulation. 2020;141:1826-1828.

    Not in our library10.1161/circulationaha.120.045826

32. 32.

    van Zuydam NR, Stiby A, Abdalla M, et al. Genome-Wide Association Study of Peripheral Artery Disease. Circ Genom Precis Med. 2021;14:e002862.

    Not in our library10.1161/circgen.119.002862

33. 33.

    Tsimikas S, Moriarty PM, Stroes ES. Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. J Am Coll Cardiol. 2021;77:1576-1589.

    Not in our library10.1016/j.jacc.2021.01.051

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.